文章预览
SCI 7 November 2024 Probiotic neoantigen delivery vectors for precision cancer immunotherapy (Nature, IF: 50.5) Andrew Redenti, Jongwon Im, Benjamin Redenti, Fangda Li, Mathieu Rouanne, Zeren Sheng, William Sun, Candice R. Gurbatri, Shunyu Huang, Meghna Komaranchath, YoungUk Jang, Jaeseung Hahn, Edward R. Ballister, Rosa L. Vincent, Ana Vardoshivilli, Tal Danino & Nicholas Arpaia CORRESPONDENCE TO: td2506@columbia.edu; na2697@cumc.columbia.edu Microbial systems have been synthetically engineered to deploy therapeutic payloads in vivo. With emerging evidence that bacteria naturally home in on tumours and modulate antitumour immunity, one promising application is the development of bacterial vectors as precision cancer vaccines. Here we engineered probiotic Escherichia coli Nissle 1917 as an antitumour vaccination platform optimized for enhanced production and cytosolic delivery of neoepitope-containing peptide arrays, with increased susceptibility to blood clearance and phagocytosis.
………………………………